Shire’s Exit Strategy from Japan Provides Bayer with Exclusive Product Rights

By Business Review Editor

Pharma Deals Review: Vol 2004 Issue 44 (Table of Contents)

Published: 4 Feb-2004

DOI: 10.3833/pdr.v2004.i44.834     ISSN: 1756-7874

Section: Distribution & Marketing



Shire Pharmaceuticals has sold Bayer the exclusive rights to develop, market and sell FOSRENOL® in Japan in a deal worth up to US$70 M...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details